Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
you are here: HomeNewsBusiness

Aurobindo Pharma gets warning letter from USFDA for API facility

The action follows the recent inspection of the facility by the US Food and Drug Administration (USFDA) in August 2021, the drugmaker said in a regulatory filing.

January 14, 2022 / 10:42 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Aurobindo Pharma on Friday said it has received a warning letter from the US health regulator for its Hyderabad-based Unit I, an API (active pharmaceutical ingredient) manufacturing facility.

The action follows the recent inspection of the facility by the US Food and Drug Administration (USFDA) in August 2021, the drugmaker said in a regulatory filing.

"The company believes that this will not impact the existing business from this facility," it noted. The drugmaker stated that it will be engaging with the regulator and is fully committed to resolving the issue at the earliest.

The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe, it noted.